SCHEMBL1899321

SCHEMBL1899321

CS(=O)(=O)N(c1ccc(Br)cc1)S(C)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.40
CA1 P00915 3/20 0.40
CA9 Q16790 2/20 0.40
CYP2A6 P11509 1/20 0.38
PLCG1 P19174 2/20 0.38
PER2 O15055 1/20 0.38
CRY1 Q16526 1/20 0.38
CRY2 Q49AN0 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
MAPT P10636 1/20 0.37
GFER P55789 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1662507 0.79 L3MBTL1 (0.41) CA2L3MBTL1MAPTGFERNPSR1
SCHEMBL12994623 0.78 MAPT (0.48) CA2CA1CA9L3MBTL1MAPT
SCHEMBL16914864 0.77 PER2 (0.39) CA2CA1CYP2A6PLCG1PER2
SCHEMBL1334344 0.76 ENPP2 (0.50) CA2CA1CA9L3MBTL1MAPT
SCHEMBL21314563 0.76 ACLY (0.30)
SCHEMBL3030207 0.76 TDP1 (0.48) CA2CA1CA9L3MBTL1MAPT
SCHEMBL5479553 0.76 APLNR (0.39) CA2CA1CA9TDP1LMNA
SCHEMBL2513199 0.75 NR3C2 (0.44) CA2CA9NPSR1SMN1; SMN2ALDH1A1
SCHEMBL18346856 0.74 PER2 (0.47) PLCG1PER2CRY1CRY2L3MBTL1
SCHEMBL2329697 0.73 SMN1; SMN2 (0.37) CA2CA1CA9PER2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420695-B2 Inhibitors of janus kinases MERCK SHARP & DOHME CORP. (US) 2013-04-16 US disclosed
US-8420695-B2 Inhibitors of janus kinases MERCK SHARP & DOHME CORP. (US) 2013-04-16 US disclosed
US-8420695-B2 Inhibitors of janus kinases MERCK SHARP & DOHME CORP. (US) 2013-04-16 US disclosed
US-20110112081-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-05-12 US disclosed
US-20110112081-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-05-12 US disclosed
US-20110112081-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112081-A1 INHIBITORS OF JANUS KINASES JAK2, JAK3, JAK1 CA2 4067/4885CA1 4779/4885CA9 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.